Baljit K. Singh

Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus

Cowden disease, a dominantly inherited syndrome characterized by a variety of proliferative lesions and predisposition to breast and thyroid cancer, has recently been linked to the polymorphic marker D10S215 on chromosome segment 10q23. Loss of heterozygosity in prostate cancer is linked to the same marker, whereas loss of heterozygosity in glioblastoma, endometrial cancer, and other malignancies also localizes to this region. Most recently, a putative tumor suppressor gene (PTEN/MMAC1) has been identified in the region between D10S215 and an adjacent, more telomeric marker (D10S541) and was found to be altered in breast cancers, prostate cancers, and glioblastomas. We examined 22 invasive breast cancers for loss of heterozygosity in the 10q23 region and found loss in 41% (9/22). There were two distinct regions of loss, including one near the D10S541 marker, with an approximately equal frequency of deletion in each. The observed pattern of deletion is consistent with the presence of a tumor suppressor gene between D10S215 and D10S541. Most of the poorly differentiated carcinomas in the case collection showed loss of heterozygosity in the region near D10S215, suggesting that this loss correlates with a poor prognosis. Genes Chromosomes Cancer 21:166–171, 1998.

Insulin-like Growth Factor-independent Effects Mediated by a C-terminal Metal-binding Domain of Insulin-like Growth Factor Binding Protein-3

Insulin-like growth factors (IGFs) play a central role in the integration of proliferative and survival responses of most mammalian cell types. IGF-binding protein-3 (IGFBP-3) influences IGF action directly as a carrier of IGFs but also modulates these actions indirectly via independent mechanisms involving interactions with plasma, extracellular matrix and cell surface molecules, conditional proteolysis, cellular uptake, and nuclear transport. Here we demonstrate that a short C-terminal metal-binding domain (MBD) of IGFBP-3 mediates binding to metals. MBD epitopes, sequestered in the intact molecule, are unmasked by incubation in the presence of ferrous (but not ferric or zinc) ions. An isolated 14-mer MBD peptide triggered apoptotic effects in stressed HEK293 cells as effectively as IGFBP-3. The MBD, which encompasses a nuclear localization sequence and an adjacent putative caveolin-binding sequence, mobilizes rapid cellular uptake and nuclear localization of unrelated proteins such as green fluorescent protein and streptavidin-horseradish peroxidase conjugate. Metal ions stimulate MBD-mediated cellular/nuclear uptake in vivo. Cross-linking studies showed a direct physical interaction of MBD with integrins αv and β1, caveolin-1, and transferrin receptor. MBD-mediated protein mobilization and pro-apoptotic effects are inhibited by nystatin but not chlorpromazine, suggesting an involvement of caveolar-mediated endocytosis. However, MBD effects are inhibited by antibodies to transferrin receptor or integrins. These results are discussed with particular reference to the cell target specificity of IGFBP-3 in disease processes such as cancer and atherosclerosis.

IDENTIFICATION OF AMINO ACID RESIDUES CRITICAL FOR THE SRC-HOMOLOGY 2 DOMAIN-DEPENDENT DOCKING OF STAT2 TO THE INTERFERON ALPHA RECEPTOR

The interaction between Src-homology 2 domains (SH2) domains and phosphorylated tyrosine residues serves a critical role in intracellular signaling. In addition to the phosphotyrosine, adjacent residues are critical mediators of the specificity of this interaction. Upon treatment of cells with interferon α (IFNα), the IFNaR1 subunit of the IFNα receptor becomes tyrosine phosphorylated at position 466. The region surrounding phosphorylated tyrosine 466 subsequently acts as a docking site for the SH2 domain of Stat2, facilitating phosphorylation of the latter and, thus, the transduction of the IFNα signal. In this report site-specific mutagenesis was employed to analyze the nature of the interaction between the SH2 domain of Stat2 and the region surrounding tyrosine 466 on IFNaR1. Mutation of the valine at the +1 position carboxyl-terminal to tyrosine 466 or of the serine at the +5 position inhibits the association of Stat2 with phosphorylated IFNaR1. Moreover, receptors mutated at either of these two positions act in a dominant manner to decrease IFNα signaling, as assayed by both Stat2 phosphorylation and expression of an IFNα-responsive reporter. The demonstration that these two residues are critical in mediating the interaction between Stat2 and IFNaR1 suggests that STAT proteins might utilize a structurally distinct subset of SH2 domains to mediate signal transduction from the cell surface to the nucleus.

Bioactive Peptides Control Receptor for Advanced Glycated End Product-Induced Elevation of Kidney Insulin Receptor Substrate 2 and Reduce Albuminuria in Diabetic Mice

BACKGROUND/AIMS Sixteen-week-old db/db mice exhibit significantly elevated blood glucose and albuminuria. Kidney mesangial cell matrix expansion and collagen IV synthesis correlate with disease progression, but the underlying mechanism is unclear. METHODS Adaptive biochemical datasets were generated in cultured 293 kidney cells and in db/db mice. RESULTS In animals receiving daily subcutaneous bolus injections (weeks 8-13) of 20 microg/day humanin or 40 microg/day protein kinase C (NPKC) (a PKC-beta2 inhibitor peptide), there was a significant reduction in albuminuria, insulin receptor substrate 2 (IRS-2) and phospho-Akt (Ser473) levels in kidney tissue extracts (p < 0.05 in all cases). Elevated IRS-2 (not IRS-1), altered Akt1 and selective phosphorylation of p-Akt/Ser473 and p-IRS-1/Ser307 (but not p-Akt/Thr308 or p-IRS-2/Ser731) are correlates of the receptor for advanced glycated end product activation and are linked to albuminuria in vivo, whereas in P38 peptide-treated animals, collagen IV synthesis can be uncoupled from albuminuria altogether. CONCLUSION Taken together, our results suggest that elevated IRS-2 and altered Akt phosphorylation may be more closely tied to the cause of diabetic kidney disease in db/db mice than mesangial matrix expansion per se, though both may originate from elevated circulatory glucose, and mesangial matrix expansion may independently exacerbate kidney dysfunction.

The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.

Conventional chemotherapy for cancer has limited specificity for cancer cells. Here, we investigate the possibility of improving the selectivity of chemotherapy by coadministering targeted biological modifier peptides. We show that the 22-amino acid metal-binding transporter domain (MBD) derived from insulin-like growth factor-binding protein-3 selectively targets cancer cells. The rate of MBD uptake by cells was measured using a panel of 54 human cancer cell lines and correlated with MBD cross-linking to cell surface transferrin receptor, caveolin 1, and integrin &bgr;. Gene array data show that MBD uptake correlates with the expression of genes associated with cellular stress-coping mechanisms commonly upregulated in cancer (nuclear factor-κB, Hsp-70B). MBD-tagged peptides designed to inhibit such mechanisms have cytotoxic effects on a broad range of human cancer cell lines. The discriminant validity of these peptides as potential cotherapeutic agents was investigated by comparing their cytotoxicity to cancer cell lines versus normal human cell counterparts. Synergies between these peptides and marginally cytotoxic levels of 5-fluorouracil were demonstrated. Biodistribution data from in-vivo experiments in mice and rats confirm that MBD-tagged peptides and proteins preferably localize to specific tissues, such as kidney and pancreas. Intracardial injection of CCRF-CEM T-cell leukemia or MDA-MB-435 cells into Rag-2 mice establishes disseminated disease within 7 days. Twenty-five-day subcutaneous administration of a three-peptide cocktail (3 mg/kg) in combination with 5-fluorouracil in Rag-2 mice with established CCRF-CEM leukemia significantly reduces splenomegaly and bone marrow cancer cell burden. In a similar experiment using MDA-MB-435 cells, MBD-tagged peptides reduced human cell burden in bone marrow. Taken together, these data suggest that MBD-tagged molecules can be used as highly selective chemosensitizers in the treatment of hematological and disseminated malignancies.

A Nuclear Complex of Rictor and Insulin Receptor Substrate-2 Is Associated with Albuminuria in Diabetic Mice

BACKGROUND Signaling events associated with diabetic nephropathy are not well understood. Triangulation of events triggered by unrelated bioactive peptides nephrilin and anephril, both of which inhibit albuminuria in diabetic mice, could reveal a common subset of events associated with albuminuria. METHODS db/db mice received 20 microg/day anephril or nephrilin for 7 weeks. Streptozotocin (STZ)-treated DBA/2J mice received 2 mg/kg nephrilin for 26 days. In both studies, urine albumin and creatinine, plasma glucose, and tissue proteins were measured by enzyme-linked immunosorbent assay (ELISA). In a safety study, DBA/2J mice received 20 mg/kg nephrilin for 26 days, and tissues from these mice were fixed in formalin for histological analysis. HEK293 human kidney cells were treated with glycated hemoglobin plus 20 microg/mL nephrilin or anephril for 24 h. RESULTS Both peptides reduced albuminuria in db/db mice compared to saline-treated animals without affecting plasma glucose or insulin. In kidney tissues, the immunoreactivities of insulin receptor substrate-2 (IRS2), phosphorylated protein kinase C (p-PKC), and serum- and glucocortocoid-inducible kinase (SGK1) were reduced. Nephrilin, but not anephril, lowered elevated SGK1 in spleens of db/db mice. In STZ-pretreated DBA/2J mice, nephrilin reduced albuminuria and the accumulation of nuclear Rictor, IRS2, and p-PKC in the kidney. In cultured kidney cells, nephrilin disrupted the association of Rictor with IRS2 and nuclear compartmentalization. Histopathological examination of tissues from mice treated with 20 mg/kg nephrilin daily for 26 days showed no significant pathology compared to saline-treated controls. CONCLUSIONS We define a subset of signaling markers closely associated with albuminuria. Mammalian target of rapamycin complex 2 (mTORC2)::IRS complexes may play a role in the nuclear accumulation, and possible downstream transcriptional effects, of p-PKC. The activity and apparent safety of nephrilin in rodents suggest a novel intervention strategy for diabetic kidney disease.